Eye for pharma pic

Opticom took the opportunity to hear and discuss What’s cooking in Pharma, at the annual Eye for Pharma’s Barcelona Conference 2017.

Buzz words such as patient empowerment, digital services, multi-stakeholder collaboration, and customer engagement confirm that the industry is clearly widening its “customer focus” to include a stronger patient centricity and closer stakeholder collaboration as well as a broader definition of offering value through innovative services.

Opticom will continue to help health companies succeed in their healthcare ecosystem. Do contact us if you would like to talk, brainstorm, and plan your next steps towards improved value propositions!

Some interesting quotes caught at Eye for Pharma Barcelona 2017:

“Technology forces us forward: pharma on its own will cause an evolution, by partnering with external partners, we will create a revolution.” (Panel discussion)

On Patient value: “We need to get patients to be proud of us – Pharma – proud of what we have achieved. We should do a better job to convince them.” (Panel discussion)

Bottom line: regardless of the value offered: “Never surprise us (patients) with any side effect!” (Ian Talmage, Senior Advisor, Bayer)

“Pharma’s role: Helping people to get better at getting better.” (Panel discussion)

“What is the most advanced pharma company when it comes to digitalization? Not just one company, but we can see indications that they are often the smaller, midsize companies, from the Nordics or Belgium.” (Dr. Frank Kumli, Executive Director, Life Sciences, EY)

Download PDF

Inbjudan top image

Hej!

Onsdagen den 6 juli arrangerar Opticom, Adxto & Mimerex ett gemensamt mingel för våra kunder inom
Life Science. Vi bjuder på rosé, sushi samt ett lättsamt samkväm med kollegor i branschen. Vi kommer
vid tillfället att informera om våra verksamheter.

Tyvärr har vi ett begränsat antal platser, så anmäl dig så snart som möjligt.
Anmäl dig (eller meddela förhinder) genom att klicka här

Vi ser fram emot att träffa dig!

Varmt välkommen önskar

Carl Michael Bergman            Helena Östregård                           Pontus Torstensson
VD Opticom                            VD Adxto                                        VD Mimerex
carl.michael@opticom.se       helena.ostregard@adxto.com        pontus.torstensson@mimerex.com

Datum: 2016-07-06
Tid: 16:00-19:00
Plats: Wisby Strands Veranda, Strandvägen 4, Visby

Anmäl dig senast 2016-07-03

Vill du veta mer om vad vi på Opticom, Adxto och Mimerex arbetar med? – besök gärna våra hemsidor

www.opticom.se     www.adxto.com     www.mimerex.com

Inbjudan bottom image

Download PDF

Just before the turn of the millennium, in 1999, the consulting and research company Opticom carried out a survey of how senior representatives of what were at that time the major global pharmaceutical companies saw the future. How well does the companies’ vision coincide with the way things are now, 15 years later?

The report, Prescription for a healthy industry, also formed the basis for a series of articles in Svenska Dagbladet/Näringsliv written by Elisabeth Sandlund. The report was partly based on in-depth interviews with 34 senior executives at what were at that time the 20 largest pharmaceutical companies. Their analysis resulted in three main points:

  • There is still a large unsatisfied need for pharmaceuticals. There is no cure for two thirds of all illnesses. The world population is getting older. New research methods are being developed all the time and there will be substantial growth in DTC (direct-to-consumer sales).
  • Quick access to market is a key to success. In the face of tougher future competition, companies must launch new innovative products quickly.
  • Company mergers slow down companies’ development processes. The top executives questioned the benefits of mergers and wondered whether they were driven by the financial markets and by financial consultants. They were the main beneficiaries of mergers – not the patients.

The winners, predicted the author of the report, will be companies that succeed in achieving a high organic growth rate, companies that sell or outsource in areas outside their own core areas and companies that focus on a small number of therapeutic areas and companies that focus their efforts on their own stores and customers. Companies will benefit from alliances with other companies and research groups, in-licensing, greater investment in research and development and strategic use of information technology.

The losers, on the other hand, would be companies with weak research portfolios but that chose to merge – those companies lose their focus and their rhythm, and therefore their competitiveness…

Article continued in links below

Links to whole article:
Click here to read the full article (in English)Translated from original Swedish by Opticom.
Click here to read the full article (in Swedish).

 

 

Download PDF

LIF, de forskande läkemedelsföretagens intresseförening invigde i torsdags, den 17e mars, sina nya lokaler på Sveavägen 63 i centrala Stockholm och vi var naturligtvis där.

LIFs VD Anders Blanck inledde med att berätta om hur de vill att de nya lokalerna ska kunna vara en mötesplats för alla som vill diskutera samverkan på vårdområdet, förutom kontor finns ett antal stora och små mötesrum att hyra. Dessutom står några arbetsplatser till förfogande för den som kanske är tillfälligt i stan och behöver en tillfällig kontorsplats i stimulerande miljö så LIF hoppas att så många som möjligt utnyttjar denna möjlighet.

LIF delar redan de här lokalerna med flera andra organisationer, IML, Leading Health Care, Swecare och Läkemedelsförsäkringen och fler kommer flytta in när nuvarande två våningsplan snart blir tre.

Politiken är en avgörande länk för att få samverkan att fungera och på invigningen representerades Socialdepartementet av Statssekreterare Agneta Karlsson som bland annat ville betona regeringens uttalade ambition att Sverige ska vara världsbäst på Life Science och att samverkan mellan alla tänkbara aktörer och på alla möjliga nivåer är helt nödvändigt för att nå det målet. Alla representanter instämde helhjärtat!

Life Science-organisationer knyter samarbetsband

Sen var det dags för Statssekreteraren att klippa bandet men för att symbolisera denna gemensamma vilja till samverkan fick alla representanter istället varsin del av bandet som de gemensamt knöt ihop till ett helt.

/Tomas Andersson
Senior Researcher, Opticom

Source: Life Science-organisationer knyter samarbetsband

Download PDF